| 4.87 0.175 (3.73%) | 04-19 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 6.22 | 1-year : | 7.27 |
| Resists | First : | 5.32 | Second : | 6.22 |
| Pivot price | 4.86 |
|||
| Supports | First : | 4.39 |
Second : | 3.8 |
| MAs | MA(5) : | 4.72 |
MA(20) : | 4.84 |
| MA(100) : | 4.15 |
MA(250) : | 4.58 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 33.8 |
D(3) : | 30.1 |
| RSI | RSI(14): 55.7 |
|||
| 52-week | High : | 7.98 | Low : | 2.25 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ DCTH ] has closed below upper band by 49.4%. Bollinger Bands are 33.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.91 - 4.93 | 4.93 - 4.95 |
| Low: | 4.56 - 4.59 | 4.59 - 4.61 |
| Close: | 4.82 - 4.87 | 4.87 - 4.91 |
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with hepatic dominant ocular melanoma to investigate objective response rate in metastatic ocular melanoma. The company also provides HEPZATO as a stand-alone medical device for sale under the CHEMOSAT Hepatic Delivery System for Melphalan trade name for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
Thu, 18 Apr 2024
Delcath Systems, Inc.'s (NASDAQ:DCTH) 11% loss last week hit both individual investors who own 54% as well as ... - Simply Wall St
Mon, 01 Apr 2024
Delcath Systems Receives Permanent J-Code (J9248) for HEPZATO™ (melphalan/Hepatic Delivery System) Effective ... - PR Newswire
Wed, 27 Mar 2024
Can Delcath Systems Inc (DCTH) Stock Rise to the Top of Healthcare Sector Wednesday? - InvestorsObserver
Wed, 27 Mar 2024
Delcath Systems, Inc. (NASDAQ:DCTH) Q4 2023 Earnings Call Transcript - Yahoo Finance
Tue, 26 Mar 2024
Delcath Systems, Inc. (DCTH) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Tue, 26 Mar 2024
Delcath Systems Inc (DCTH) Q4 2023 Earnings Call Transcript - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 0 (M) |
| Shares Float | 25 (M) |
| Held by Insiders | 2.11e+007 (%) |
| Held by Institutions | 3.2 (%) |
| Shares Short | 833 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -3.805e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 97.2 % |
| Return on Equity (ttm) | -84.6 % |
| Qtrly Rev. Growth | 2.06e+006 % |
| Gross Profit (p.s.) | -26.17 |
| Sales Per Share | -1027.59 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -3 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -31 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | -0.3 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 4.23 |
| Dividend | 0 |
| Forward Dividend | 936340 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|